French public health agencies

Created by the 9 August 2004law on public health policy, the High Council of Public Health is an instance of expertise that incorporates and expands the mission of the Higher Council of Public Hygiene of France and those of the High Committee public health, serving since 1848 and 1991 respectively. It includes several committees related to vaccinology such as: technical vaccination's committee  and specialized transmissible deseases commission.


The National Institute for Prevention and Health Education is a public institution established by the 4 March 2002 Law  on patients' rights and the quality of the health system. The Institute is a public health actor responsible for implementing the policies of prevention and health education in the context of public health policy set by the Government.


The French Institute for Public Health Surveillance (Institut de veille sanitaire, InVS), a governmental institution reporting to the Ministry of Health, is responsible for surveillance and alert in all domains of public health. Created in 1998 to reinforce health surveillance and the safety of products intended for human use, its mandates were enlarged by the Public Health Policy Act of 2004, in order to meet the new challenges highlighted by recent health and emerging risks. The unit for diseases preventable by vaccination and vaccination coverage conducts activities to monitor diseases preventable by vaccination, allowing the epidemiological impact of vaccination programmes implemented in the framework of the immunisation schedule to be evaluated.

A new project is starting this year to put in place by 2016 a new public health institute insuring all epidemiological monitoring and alerts, crisis intervention, and health prevention and promotion, activities currently leading by three institutes : EPRUS, INPES and InVS. This new institute should improve harmonization and continuity for all this missions.

The National Security Agency of Medicines and Health Products (MSNA) was created by the 29 December 2011 Law on the strengthening of the medicines and health products safety. It is a public institution under the supervision of the Ministry of Health. Its two central missions are: to provide equitable access to innovation for all patients and ensure the safety of health products throughout their life cycle, from initial trials to surveillance after authorization on the market.